Newgenivf Group Ltd cash flow statement

In fiscal 2025, Newgenivf Group Ltd's operations generated −$10.9m of cash; it spent $135,025 on capital projects, leaving free cash flow of −$11.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Newgenivf Group Ltd: cash flow statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	1	2	−2	−8	−11
Depreciation and amortisation	0	0	0	0	0
Stock-based pay	0	0	—	−3	—
Capital spending	0	0	0	0	0
Free cash flow	1	2	−2	−8	−11
Free cash flow after stock pay	1	1	—	−6	—
Shares issued	—	—	0	—	13

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BMGL vs NIVF CCM vs NIVF NIVF vs SNDA

More: Health Care Facilities stocks compared, Health Care sector, rankings of US companies

Figures from Newgenivf Group Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Newgenivf Group Ltd.